HDL Cholesterol: Physiology, Pathophysiology, and Management

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Numerous epidemiological studies have identified high-density lipoprotein cholesterol (HDL) to be an independent risk factor for coronary heart disease (CHD). HDL is an emerging therapeutic target that could rival the impact of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) on LDL and CHD risk reduction. HDL metabolism, HDL kinetics, the concentration of various HDL subclasses, and other genetic factors affecting HDL functionality may all contribute to the anti-atherogenic properties of HDL; thus, standard plasma measurement may not capture the full range of HDL effects. Algorithms have been suggested to treat low HDL levels in subgroups of patients; however, no formal HDL target goals or treatment guidelines have been implemented as there is a lack of strong clinical evidence to support effective pharmacologic therapy for primary risk reduction. Available therapies have a modest impact on serum HDL levels; however, emerging therapies could have a more significant influence.

Original languageEnglish (US)
Pages (from-to)268-314
Number of pages47
JournalCurrent Problems in Cardiology
Volume32
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

HDL Cholesterol
Cholesterol
Risk Reduction Behavior
Coronary Disease
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Epidemiologic Studies
Oxidoreductases
Guidelines

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

HDL Cholesterol : Physiology, Pathophysiology, and Management. / Link, Jeffrey J.; Rohatgi, Anand K; de Lemos, James A.

In: Current Problems in Cardiology, Vol. 32, No. 5, 05.2007, p. 268-314.

Research output: Contribution to journalArticle

@article{a737d814662d483e9fb6368f3c55ca80,
title = "HDL Cholesterol: Physiology, Pathophysiology, and Management",
abstract = "Numerous epidemiological studies have identified high-density lipoprotein cholesterol (HDL) to be an independent risk factor for coronary heart disease (CHD). HDL is an emerging therapeutic target that could rival the impact of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) on LDL and CHD risk reduction. HDL metabolism, HDL kinetics, the concentration of various HDL subclasses, and other genetic factors affecting HDL functionality may all contribute to the anti-atherogenic properties of HDL; thus, standard plasma measurement may not capture the full range of HDL effects. Algorithms have been suggested to treat low HDL levels in subgroups of patients; however, no formal HDL target goals or treatment guidelines have been implemented as there is a lack of strong clinical evidence to support effective pharmacologic therapy for primary risk reduction. Available therapies have a modest impact on serum HDL levels; however, emerging therapies could have a more significant influence.",
author = "Link, {Jeffrey J.} and Rohatgi, {Anand K} and {de Lemos}, {James A}",
year = "2007",
month = "5",
doi = "10.1016/j.cpcardiol.2007.01.004",
language = "English (US)",
volume = "32",
pages = "268--314",
journal = "Current Problems in Cardiology",
issn = "0146-2806",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - HDL Cholesterol

T2 - Physiology, Pathophysiology, and Management

AU - Link, Jeffrey J.

AU - Rohatgi, Anand K

AU - de Lemos, James A

PY - 2007/5

Y1 - 2007/5

N2 - Numerous epidemiological studies have identified high-density lipoprotein cholesterol (HDL) to be an independent risk factor for coronary heart disease (CHD). HDL is an emerging therapeutic target that could rival the impact of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) on LDL and CHD risk reduction. HDL metabolism, HDL kinetics, the concentration of various HDL subclasses, and other genetic factors affecting HDL functionality may all contribute to the anti-atherogenic properties of HDL; thus, standard plasma measurement may not capture the full range of HDL effects. Algorithms have been suggested to treat low HDL levels in subgroups of patients; however, no formal HDL target goals or treatment guidelines have been implemented as there is a lack of strong clinical evidence to support effective pharmacologic therapy for primary risk reduction. Available therapies have a modest impact on serum HDL levels; however, emerging therapies could have a more significant influence.

AB - Numerous epidemiological studies have identified high-density lipoprotein cholesterol (HDL) to be an independent risk factor for coronary heart disease (CHD). HDL is an emerging therapeutic target that could rival the impact of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) on LDL and CHD risk reduction. HDL metabolism, HDL kinetics, the concentration of various HDL subclasses, and other genetic factors affecting HDL functionality may all contribute to the anti-atherogenic properties of HDL; thus, standard plasma measurement may not capture the full range of HDL effects. Algorithms have been suggested to treat low HDL levels in subgroups of patients; however, no formal HDL target goals or treatment guidelines have been implemented as there is a lack of strong clinical evidence to support effective pharmacologic therapy for primary risk reduction. Available therapies have a modest impact on serum HDL levels; however, emerging therapies could have a more significant influence.

UR - http://www.scopus.com/inward/record.url?scp=34247619743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247619743&partnerID=8YFLogxK

U2 - 10.1016/j.cpcardiol.2007.01.004

DO - 10.1016/j.cpcardiol.2007.01.004

M3 - Article

C2 - 17481993

AN - SCOPUS:34247619743

VL - 32

SP - 268

EP - 314

JO - Current Problems in Cardiology

JF - Current Problems in Cardiology

SN - 0146-2806

IS - 5

ER -